AdJane
Pioneers in the field of engineered OMVs
AdJane is a clinical-stage biotechnology company advancing a portfolio of vaccines built on our proprietary OMV-Vacc platform. As pioneers in the field of engineered Outer Membrane Vescicles (OMVs) derived from Neisseira meningitidis, our lead programs target high-burden, under-served infectious diseases with significant global health impact.
Over three decades of experience
Leveraging three decades of experience in research and development of vaccines by the Netherlands Vaccine Institute (NVI), AdJane is strategically partnered with Intravacc to progress multiple unique vaccine candidates and adjuvants along clinical development.
Our Mission
Our goal is to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world.
Our Vision
By harnessing the body’s natural immune response, we aim to amplify the vaccines of tomorrow.
Our Team
AdJane is a first-of-its-kind biotechnology company on a mission to address significant unmet medical needs while being entirely female-led. Each of our team members brings their unique skill set and jointly contributes to countering infectious disease, antimicrobial resistance, and delivering tangible social impact. Scientists, innovators, and entrepreneurs dedicated to advancing AdJane’s mission of amplifying the vaccines of tomorrow.
Anita Gashi
Director
Marlène Goedvolk
Finance Director
Corine Kruiswijk
Scientific Director
Press Release
AdJane Announces its Official Launch as a Leader in Vaccine Adjuvants
Delft, Netherlands, October 24, 2024 – AdJane is proud to announce its official launch as a pioneer in the field of vaccine adjuvants, dedicated to enhancing the efficacy of vaccines. With commitment to innovation and excellence, AdJane aims to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world. Our mission is to amplify the vaccines of tomorrow.
The launch of AdJane comes at a pivotal time as the global healthcare community continues to address emerging infectious diseases and ongoing public health challenges. Vaccine adjuvants play a crucial role in improving the body’s immune response to vaccines. By optimizing vaccine formulation, AdJane’s adjuvants enhance antigen presentation and promote a more robust and lasting immunity. The company’s commitment to innovation and quality positions it at the forefront of the vaccine sector.
About the company
AdJane specializes in the development of vaccine adjuvants aimed at enhancing vaccine efficacy. At the heart of AdJane’s innovations lies our proprietary Ada-24 adjuvant. This adjuvant has been developed through a strategic collaboration and long-term partnership with Intravacc, a pioneer and leader in translational vaccinology. Ada-24 is based on and leverages the features of Outer Membrane Vesicles (OMVs), derived from gram negative bacteria and further detoxified, resulting in a safe adjuvant already tested in humans. These nanoparticles are a powerful tool in enhancing the immune response due to their versatile and adaptable nature. Various studies have shown that the inclusion of our proprietary Ada-24 adjuvant elicits a broad immune response, outperforming conventional adjuvants. Adjane will continue its efforts to develop novel adjuvants and looks forward to partnership opportunities towards commercializing Ada-24.
For additional inquiries, please contact us at info@adjane.com